Skip to main content
×
Home
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 22
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Rein, David B. Wittenborn, John S. Smith, Bryce D. Liffmann, Danielle K. and Ward, John W. 2015. The Cost-effectiveness, Health Benefits, and Financial Costs of New Antiviral Treatments for Hepatitis C Virus. Clinical Infectious Diseases, Vol. 61, Issue. 2, p. 157.


    Anderson, Roger T. Baran, Robert W. Dietz, Birgitta Kallwitz, Eric Erickson, Pennifer and Revicki, Dennis A. 2014. Development and initial psychometric evaluation of the hepatitis C virus-patient-reported outcomes (HCV-PRO) instrument. Quality of Life Research, Vol. 23, Issue. 2, p. 561.


    Hauser, Goran Awad, Tahany Brok, Jesper Thorlund, Kristian Štimac, Davor Mabrouk, Mahasen Gluud, Christian Gluud, Lise Lotte and Hauser, Goran 2014. Cochrane Database of Systematic Reviews.


    2014. Aplicación del análisis coste-efectividad de los medicamentos y los programas de salud en la planificación sanitaria.


    Razavi, Homie ElKhoury, Antoine C. Elbasha, Elamin Estes, Chris Pasini, Ken Poynard, Thierry and Kumar, Ritesh 2013. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology, Vol. 57, Issue. 6, p. 2164.


    Sroczynski, Gaby and Siebert, Uwe 2013. Viral hepatitis: Cost-effectiveness of direct-acting antivirals for chronic hepatitis C. Nature Reviews Gastroenterology & Hepatology, Vol. 10, Issue. 10, p. 572.


    Hassan, Qussai Roche, Bruno Buffet, Camille Bessede, Thomas Samuel, Didier Charpentier, Bernard and Durrbach, Antoine 2012. Liver-kidney recipients with chronic viral hepatitis C treated with interferon-alpha. Transplant International, Vol. 25, Issue. 9, p. 941.


    Siebert, Uwe Alagoz, Oguzhan Bayoumi, Ahmed M. Jahn, Beate Owens, Douglas K. Cohen, David J. and Kuntz, Karen M. 2012. State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. Value in Health, Vol. 15, Issue. 6, p. 812.


    Townsend, Rebecca McEwan, Phil Kim, Ray and Yuan, Yong 2011. Structural Frameworks and Key Model Parameters in Cost-Effectiveness Analyses for Current and Future Treatments of Chronic Hepatitis C. Value in Health, Vol. 14, Issue. 8, p. 1068.


    Dintsios, Charalabos-Markos Haverkamp, Alexander Wiegand, Johannes Gerlach, Tilman Wedemeyer, Heiner Pape, Gerd Manns, Michael Peter and Krauth, Christian 2010. Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany. European Journal of Gastroenterology & Hepatology, Vol. 22, Issue. 3, p. 278.


    Sroczynski, G. Esteban, E. Conrads-Frank, A. Schwarzer, R. Mühlberger, N. Wright, D. Zeuzem, S. and Siebert, U. 2010. Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C. Journal of Viral Hepatitis, Vol. 17, Issue. 1, p. 34.


    Awad, Tahany Thorlund, Kristian Hauser, Goran Mabrouk, Mahasen Stimac, Davor Gluud, Christian and Awad, Tahany 2009. Cochrane Database of Systematic Reviews.


    Awad, Tahany Thorlund, Kristian Hauser, Goran Mabrouk, Mahasen Stimac, Davor Gluud, Christian and Awad, Tahany 2009. Cochrane Database of Systematic Reviews.


    Awad, Tahany Brok, Jesper Thorlund, Kristian Hauser, Goran Stimac, Davor Mabrouk, Mahasen Gluud, Christian Gluud, Lise Lotte and Awad, Tahany 2009. Cochrane Database of Systematic Reviews.


    Awad, Tahany Thorlund, Kristian Hauser, Goran Mabrouk, Mahasen Stimac, Davor Gluud, Christian and Awad, Tahany 2009. Cochrane Database of Systematic Reviews.


    Awad, Tahany Thorlund, Kristian Hauser, Goran Mabrouk, Mahasen Stimac, Davor Gluud, Christian and Awad, Tahany 2009. Cochrane Database of Systematic Reviews.


    Awad, Tahany Thorlund, Kristian Hauser, Goran Mabrouk, Mahasen Stimac, Davor Gluud, Christian and Awad, Tahany 2009. Cochrane Database of Systematic Reviews.


    Grishchenko, Marina Grieve, Richard D. Sweeting, Michael J. De Angelis, Daniela Thomson, Brian J. Ryder, Stephen D. and Irving, William L. 2009. Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. International Journal of Technology Assessment in Health Care, Vol. 25, Issue. 02, p. 171.


    Mühlberger, Nikolai Schwarzer, Ruth Lettmeier, Beate Sroczynski, Gaby Zeuzem, Stefan and Siebert, Uwe 2009. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health, Vol. 9, Issue. 1,


    Siebert, Uwe Sroczynski, Gaby Aidelsburger, Pamela Rossol, Siegbert Wasem, Jürgen Manns, Michael P. McHutchison, John G. and Wong, John B. 2009. Clinical Effectiveness and Cost Effectiveness of Tailoring Chronic Hepatitis C Treatment with Peginterferon Alpha-2b Plus Ribavirin to HCV Genotype and Early Viral Response. PharmacoEconomics, Vol. 27, Issue. 4, p. 341.


    ×
  • International Journal of Technology Assessment in Health Care, Volume 21, Issue 1
  • January 2005, pp. 55-65

Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: A health technology assessment commissioned by the German Federal Ministry of Health and Social Security

  • Uwe Siebert (a1) and Gaby Sroczynski (a1)
  • DOI: http://dx.doi.org/10.1017/S0266462305050075
  • Published online: 01 January 2005
Abstract

Objectives: The purpose of this health technology assessment (HTA), commissioned by the German Federal Ministry of Health and Social Security, was to systematically review the evidence for the effectiveness and cost-effectiveness of antiviral treatment (AVT) with interferon (INF) or peginterferon (PegIFN) in combination with ribavirin (RBV) in treatment-naïve patients with chronic hepatitis C (CHC) and to apply these data in the context of the German health-care system.

Methods: We performed a systematic literature search on effectiveness and cost-effectiveness of AVT and summarized results using meta-analysis and evidence tables. We applied the German Hepatitis C Model (GEHMO), a decision-analytic Markov model, to determine long-term clinical effectiveness, costs, and incremental cost-effectiveness ratios (ICER) of the examined treatment strategies. Model parameters were derived from German databases, published international randomized clinical trials (RCT), and a Cochrane Review.

Results: Overall, nine RCTs, two HTA reports, one Cochrane review, two meta-analyses, and seven economic evaluations met the inclusion criteria. These studies indicate that PegIFN+RBV achieved the highest sustained virological response rates (SVR) (54–61 percent), followed by IFN+RBV (38–54 percent) and IFN monotherapy (11–21 percent). Based on our meta-analysis, PegIFN+RBV reduced cases without SVR by 17 percent compared with INF+RBV. International cost-effectiveness studies indicate that INF+RBV is cost-effective when compared with INF monotherapy. For PegIFN+RBV, our decision analysis yielded an ICER of €9,800 per quality-adjusted life-year gained.

Conclusions: This HTA suggests that initial combination therapy prolongs life, improves quality of life, and is cost-effective in patients with CHC. Peginterferon plus ribavirin is the most effective and efficient treatment among the examined options. However, because not all chronic hepatitis C patients will develop progressive liver disease, a thorough assessment of the eligibility and appropriateness of treatment with combination therapy must be performed in each individual patient.

Copyright
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Journal of Technology Assessment in Health Care
  • ISSN: 0266-4623
  • EISSN: 1471-6348
  • URL: /core/journals/international-journal-of-technology-assessment-in-health-care
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords: